These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 26317790)

  • 1. IGFBP2 modulates the chemoresistant phenotype in esophageal adenocarcinoma.
    Myers AL; Lin L; Nancarrow DJ; Wang Z; Ferrer-Torres D; Thomas DG; Orringer MB; Lin J; Reddy RM; Beer DG; Chang AC
    Oncotarget; 2015 Sep; 6(28):25897-916. PubMed ID: 26317790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of EGFR-DNA-PKcs pathway by IGFBP2 protects esophageal adenocarcinoma cells from acidic bile salts-induced DNA damage.
    Zhou Z; Lu H; Zhu S; Gomaa A; Chen Z; Yan J; Washington K; El-Rifai W; Dang C; Peng D
    J Exp Clin Cancer Res; 2019 Jan; 38(1):13. PubMed ID: 30626422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. microRNAs: Key regulators of chemotherapy response and metastatic potential via complex control of target pathways in esophageal adenocarcinoma.
    Matuszcak C; Lindner K; Eichelmann AK; Hussey DJ; Haier J; Hummel R
    Surg Oncol; 2018 Sep; 27(3):392-401. PubMed ID: 30217293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systems Biology Analyses Show Hyperactivation of Transforming Growth Factor-β and JNK Signaling Pathways in Esophageal Cancer.
    Blum AE; Venkitachalam S; Ravillah D; Chelluboyina AK; Kieber-Emmons AM; Ravi L; Kresak A; Chandar AK; Markowitz SD; Canto MI; Wang JS; Shaheen NJ; Guo Y; Shyr Y; Willis JE; Chak A; Varadan V; Guda K
    Gastroenterology; 2019 May; 156(6):1761-1774. PubMed ID: 30768984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low miR-187 expression promotes resistance to chemoradiation therapy in vitro and correlates with treatment failure in patients with esophageal adenocarcinoma.
    Lynam-Lennon N; Bibby BA; Mongan AM; Marignol L; Paxton CN; Geiersbach K; Bronner MP; O'Sullivan J; Reynolds J; Maher SG
    Mol Med; 2016 May; 22():388-97. PubMed ID: 27254108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2.
    Chung LY; Tang SJ; Sun GH; Chou TY; Yeh TS; Yu SL; Sun KH
    Clin Cancer Res; 2012 Aug; 18(15):4037-47. PubMed ID: 22696230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JNK mediates insulin-like growth factor binding protein 2/integrin alpha5-dependent glioma cell migration.
    Mendes KN; Wang GK; Fuller GN; Zhang W
    Int J Oncol; 2010 Jul; 37(1):143-53. PubMed ID: 20514406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 Confers Resistance to Foretinib Inhibition of MET-Amplified Esophageal Adenocarcinoma Cells.
    Goltsov AA; Fang B; Pandita TK; Maru DM; Swisher SG; Hofstetter WL
    Ann Thorac Surg; 2018 Feb; 105(2):363-370. PubMed ID: 29223420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NHERF1 Enhances Cisplatin Sensitivity in Human Cervical Cancer Cells.
    Tao T; Yang X; Qin Q; Shi W; Wang Q; Yang Y; He J
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28085111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of Dickkopf-3 overexpression in esophageal adenocarcinoma.
    Wang Z; Lin L; Thomas DG; Nadal E; Chang AC; Beer DG; Lin J
    J Thorac Cardiovasc Surg; 2015 Aug; 150(2):377-385.e2. PubMed ID: 26093488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and characterization of stemlike cells in human esophageal adenocarcinoma and normal epithelial cell lines.
    Zhao R; Quaroni L; Casson AG
    J Thorac Cardiovasc Surg; 2012 Nov; 144(5):1192-9. PubMed ID: 22980068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subtypes of Barrett's oesophagus and oesophageal adenocarcinoma based on genome-wide methylation analysis.
    Yu M; Maden SK; Stachler M; Kaz AM; Ayers J; Guo Y; Carter KT; Willbanks A; Heinzerling TJ; O'Leary RM; Xu X; Bass A; Chandar AK; Chak A; Elliott R; Willis JE; Markowitz SD; Grady WM
    Gut; 2019 Mar; 68(3):389-399. PubMed ID: 29884612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma.
    Kang Z; Yu Y; Zhu YJ; Davis S; Walker R; Meltzer PS; Helman LJ; Cao L
    Oncogene; 2014 Dec; 33(50):5697-705. PubMed ID: 24292683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties.
    Xu Y; Jiang Z; Zhang Z; Sun N; Zhang M; Xie J; Li T; Hou Y; Wu D
    J Cell Biochem; 2014 Jun; 115(6):1112-21. PubMed ID: 24356998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.
    Lu H; Wang L; Gao W; Meng J; Dai B; Wu S; Minna J; Roth JA; Hofstetter WL; Swisher SG; Fang B
    Mol Cancer Ther; 2013 Dec; 12(12):2864-73. PubMed ID: 24130049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-induced expression of EpCAM contributes to therapy resistance in esophageal adenocarcinoma.
    Sun X; Martin RCG; Zheng Q; Farmer R; Pandit H; Li X; Jacob K; Suo J; Li Y
    Cell Oncol (Dordr); 2018 Dec; 41(6):651-662. PubMed ID: 30116994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of MIIP regulates human breast cancer proliferation, invasion and migration by mediated by IGFBP2.
    Du Y; Wang P
    Pathol Res Pract; 2019 Jul; 215(7):152440. PubMed ID: 31078343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer.
    Lindner K; Borchardt C; Schöpp M; Bürgers A; Stock C; Hussey DJ; Haier J; Hummel R
    J Exp Clin Cancer Res; 2014 Sep; 33(1):73. PubMed ID: 25175076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TGM2: a cell surface marker in esophageal adenocarcinomas.
    Leicht DT; Kausar T; Wang Z; Ferrer-Torres D; Wang TD; Thomas DG; Lin J; Chang AC; Lin L; Beer DG
    J Thorac Oncol; 2014 Jun; 9(6):872-81. PubMed ID: 24828664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
    Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.